PCM
NKTR icon

Palisade Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Palisade Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-667
Closed -$336K – 426
2019
Q1 		$336K Sell
667
-150
-18% -$88.9K 0.01% 388
2018
Q4 		$403K Buy
817
+84
+11% +$50.7K 0.01% 389
2018
Q3 		$671K Buy
+733
New +$626K 0.02% 382

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Palisade Capital Management's NKTR Position: Q2 2019 in Review

Palisade Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2019, closing a stake of 667 shares — an estimated $336K sold.

Palisade Capital Management first reported a position in NKTR in Q3 2018 and held it in 3 quarters. The position peaked at $671K in Q3 2018. 336 funds tracked by Wall St. Rank hold NKTR as of Q2 2019.

  • Palisade Capital Management reported no remaining Nektar Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Palisade Capital Management sold 667 Nektar Therapeutics shares in Q2 2019, an estimated $336K.
  • Palisade Capital Management first reported a position in Nektar Therapeutics in Q3 2018 and held it in 3 quarters.
  • Palisade Capital Management's Nektar Therapeutics position peaked at $671K in Q3 2018.
  • 336 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2019.

Based on Palisade Capital Management's 13F filing for Q2 2019, filed 6 Aug 2019.